tiprankstipranks
Advertisement
Advertisement

RYTM Stock Latest News

Moderna upgraded, Allstate downgraded: Wall Street’s top analyst calls
The FlyModerna upgraded, Allstate downgraded: Wall Street’s top analyst calls
8d ago
ALL
EPM
Rhythm Pharmaceuticals initiated with a Hold at Deutsche Bank
PremiumThe Fly
Rhythm Pharmaceuticals initiated with a Hold at Deutsche Bank
8d ago
RYTM
Rhythm Pharmaceuticals: Buy Rating Reiterated as Japan Approval Extends Imcivree Growth, $150 Price Target Unchanged
PremiumRatings
Rhythm Pharmaceuticals: Buy Rating Reiterated as Japan Approval Extends Imcivree Growth, $150 Price Target Unchanged
11d ago
RYTM
EMANATE Phase 3 Completion Puts Rhythm’s Genetic Obesity Strategy in Focus
PremiumCompany Announcements
EMANATE Phase 3 Completion Puts Rhythm’s Genetic Obesity Strategy in Focus
1M ago
RYTM
Rhythm Pharmaceuticals price target raised to $155 from $141 at RBC Capital
PremiumThe Fly
Rhythm Pharmaceuticals price target raised to $155 from $141 at RBC Capital
1M ago
RYTM
Rhythm Pharmaceuticals price target raised to $154 from $151 at Canaccord
PremiumThe FlyRhythm Pharmaceuticals price target raised to $154 from $151 at Canaccord
1M ago
RYTM
Rhythm Pharmaceuticals price target raised to $143 from $142 at Citi
Premium
The Fly
Rhythm Pharmaceuticals price target raised to $143 from $142 at Citi
1M ago
RYTM
Rhythm Pharmaceuticals price target raised to $160 from $155 at Citizens
Premium
The Fly
Rhythm Pharmaceuticals price target raised to $160 from $155 at Citizens
1M ago
RYTM
Imcivree’s Strong aHO Momentum and Expanding Market Access Support Buy Rating; $149 Price Target Reiterated
PremiumRatings
Imcivree’s Strong aHO Momentum and Expanding Market Access Support Buy Rating; $149 Price Target Reiterated
1M ago
RYTM
Rhythm Pharmaceuticals Earnings Call Signals Momentum
PremiumCompany Announcements
Rhythm Pharmaceuticals Earnings Call Signals Momentum
1M ago
RYTM
Rhythm Pharmaceuticals Reports Promising Phase 2 Obesity Data
PremiumCompany Announcements
Rhythm Pharmaceuticals Reports Promising Phase 2 Obesity Data
1M ago
8K
RYTM
Rhythm Pharmaceuticals’ RM-718 shows efficacy in Phase 2 obesity trial
PremiumThe Fly
Rhythm Pharmaceuticals’ RM-718 shows efficacy in Phase 2 obesity trial
1M ago
RYTM
RYTM Earnings this Week: How Will it Perform?
PremiumPre-EarningsRYTM Earnings this Week: How Will it Perform?
1M ago
RYTM
Analyst Reaffirms Buy on Rhythm as Imcivree Platform Expansion and Next‑Gen MC4R Assets Underpin Overweight Rating and $145 Price Target
Premium
Ratings
Analyst Reaffirms Buy on Rhythm as Imcivree Platform Expansion and Next‑Gen MC4R Assets Underpin Overweight Rating and $145 Price Target
1M ago
RYTM
Rhythm Pharmaceuticals initiated with an Overweight at JPMorgan
Premium
The Fly
Rhythm Pharmaceuticals initiated with an Overweight at JPMorgan
1M ago
RYTM
What the $10B Crinetics Deal & $2.9B Soleno Acquisition Might Say About Palatin’s Rare-Obesity Opportunity
PremiumTipRanks Newswire
What the $10B Crinetics Deal & $2.9B Soleno Acquisition Might Say About Palatin’s Rare-Obesity Opportunity
2M ago
PTN
CRNX
Rhythm’s Setmelanotide Extension Study: What Long-Term Data Could Mean for RYTM
PremiumCompany Announcements
Rhythm’s Setmelanotide Extension Study: What Long-Term Data Could Mean for RYTM
2M ago
RYTM
Rhythm Pharmaceuticals price target raised to $141 from $137 at RBC Capital
PremiumThe Fly
Rhythm Pharmaceuticals price target raised to $141 from $137 at RBC Capital
2M ago
RYTM
Rhythm Pharmaceuticals Stockholders Back Board, Governance Proposals
PremiumCompany Announcements
Rhythm Pharmaceuticals Stockholders Back Board, Governance Proposals
2M ago
8K
RYTM
Palatin Technologies Is Pursuing the Next Generation of MC4R. Rhythm Just Reinforced Why That Matters
PremiumTipRanks NewswirePalatin Technologies Is Pursuing the Next Generation of MC4R. Rhythm Just Reinforced Why That Matters
3M ago
LLY
NVO
Rhythm Pharmaceuticals: Buy Rating Reaffirmed as Strong PWS Data Lift 2033 Outlook and Price Target Raised to $151 from $143
Premium
Ratings
Rhythm Pharmaceuticals: Buy Rating Reaffirmed as Strong PWS Data Lift 2033 Outlook and Price Target Raised to $151 from $143
3M ago
RYTM
Rhythm Pharmaceuticals price target raised to $151 from $143 at Canaccord
Premium
The Fly
Rhythm Pharmaceuticals price target raised to $151 from $143 at Canaccord
3M ago
RYTM

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >